Format

Send to

Choose Destination
Trends Mol Med. 2013 Nov;19(11):685-94. doi: 10.1016/j.molmed.2013.08.007. Epub 2013 Sep 26.

TRAIL on trial: preclinical advances in cancer therapy.

Author information

1
Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand, or TRAIL, is a promising anticancer agent as it can induce apoptosis in a wide range of cancers whilst generally sparing non-malignant cells. However, the translation of TRAIL into the clinic has been confounded by its short half-life, inadequate delivery methods, and TRAIL-resistant cancer cell populations. In this review, we discuss how TRAIL has been functionalized to diversify its traditional tumor-killing role and novel strategies to facilitate its effective deployment in preclinical cancer models. The successes and failures of the most recent clinical trials using TRAIL agonists are highlighted and we provide a perspective for improving its clinical implementation.

KEYWORDS:

TRAIL; apoptosis; cancer; stem cells; targeted therapy

PMID:
24076237
PMCID:
PMC3880796
DOI:
10.1016/j.molmed.2013.08.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center